Paradoxical stimulation of matrix metalloproteinase-9 expression in HT1080 cells by a broad-spectrum hydroxamate-based matrix metalloproteinase inhibitor

Annals of the New York Academy of Sciences

Volumn 878, Issue , 1999, Pages 744-746

  Maquoi, E ^a   Munaut, C ^a   Colige, A ^a   Lambert, C ^a   Frankenne, F ^a   Noel A ^a   Grams, F ^b   Krell, H W ^b   Foidart, J M ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; GELATINASE A; GELATINASE B; HYDROXAMIC ACID DERIVATIVE; MATRIX METALLOPROTEINASE INHIBITOR;

CONFERENCE PAPER;

EID: 0032837743     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb07779.x     Document Type: Conference Paper

References (3)

1. 1. Talbot, D.C. & P.D. Brown. 1996. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur. J. Cancer, 14: 2528-2533.
2. 2. Maquoi, E., A. Noél, F. Frankenne, H. Angliker, G. Murphy & J.M. Foidart. 1998. Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin inhibitor. FEBS Lett. 424: 262-266.
3. 3. Campion, C., J.P. Dickens & M.J. Crimmin. PCT Patent Application, WO 90/05719, 1990.